Recent developments on coronavirus main protease/3C like protease inhibitors.
Identifieur interne : 001876 ( Main/Exploration ); précédent : 001875; suivant : 001877Recent developments on coronavirus main protease/3C like protease inhibitors.
Auteurs : Qi Zhao [États-Unis] ; Erin Weber ; Haitao YangSource :
- Recent patents on anti-infective drug discovery [ 2212-4071 ] ; 2013.
Descripteurs français
- KwdFr :
- Brevets comme sujet, Conception de médicament, Cristallographie aux rayons X, Cysteine endopeptidases (), Cysteine endopeptidases (métabolisme), Humains, Inhibiteurs de protéases (), Inhibiteurs de protéases (pharmacologie), Structure moléculaire, Syndrome respiratoire aigu sévère (virologie), Évaluation préclinique de médicament ().
- MESH :
- métabolisme : Cysteine endopeptidases.
- pharmacologie : Inhibiteurs de protéases.
- virologie : Syndrome respiratoire aigu sévère.
- Brevets comme sujet, Conception de médicament, Cristallographie aux rayons X, Cysteine endopeptidases, Humains, Inhibiteurs de protéases, Structure moléculaire, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Crystallography, X-Ray, Cysteine Endopeptidases (chemistry), Cysteine Endopeptidases (metabolism), Drug Design, Drug Evaluation, Preclinical (methods), Humans, Molecular Structure, Patents as Topic, Protease Inhibitors (chemistry), Protease Inhibitors (pharmacology), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , chemistry : Cysteine Endopeptidases, Protease Inhibitors.
- chemical , metabolism : Cysteine Endopeptidases.
- methods : Drug Evaluation, Preclinical.
- chemical , pharmacology : Protease Inhibitors.
- virology : Severe Acute Respiratory Syndrome.
- Crystallography, X-Ray, Drug Design, Humans, Molecular Structure, Patents as Topic.
Abstract
Coronaviruses have been thrust into the spotlight by the recurring novel human coronavirus infections following the 2003 SARS pandemic. In the years since the initial SARS outbreak, the arsenal to fight this virus family has been significantly increased by the rapid growth of coronavirus research. Among the potential viral drug targets, coronavirus 3C like proteases (3Cl) have emerged as the most popular drug target. A number of patented inhibitors with promising clinical potential have been developed via different methods of drug discovery, including virtual screening, natural product isolation and structure assisted rational drug design. This review serves as a summary of the progress in both the method of drug discovery and the related inhibitors against the coronavirus 3Cl protease.
DOI: 10.2174/1574891x113089990017
PubMed: 23879823
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001165
- to stream PubMed, to step Curation: 001165
- to stream PubMed, to step Checkpoint: 001117
- to stream Ncbi, to step Merge: 002711
- to stream Ncbi, to step Curation: 002711
- to stream Ncbi, to step Checkpoint: 002711
- to stream Main, to step Merge: 001882
- to stream Main, to step Curation: 001876
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent developments on coronavirus main protease/3C like protease inhibitors.</title>
<author><name sortKey="Zhao, Qi" sort="Zhao, Qi" uniqKey="Zhao Q" first="Qi" last="Zhao">Qi Zhao</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520, USA. qi.zhao@yale.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weber, Erin" sort="Weber, Erin" uniqKey="Weber E" first="Erin" last="Weber">Erin Weber</name>
</author>
<author><name sortKey="Yang, Haitao" sort="Yang, Haitao" uniqKey="Yang H" first="Haitao" last="Yang">Haitao Yang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23879823</idno>
<idno type="pmid">23879823</idno>
<idno type="doi">10.2174/1574891x113089990017</idno>
<idno type="wicri:Area/PubMed/Corpus">001165</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001165</idno>
<idno type="wicri:Area/PubMed/Curation">001165</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001165</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001117</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001117</idno>
<idno type="wicri:Area/Ncbi/Merge">002711</idno>
<idno type="wicri:Area/Ncbi/Curation">002711</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002711</idno>
<idno type="wicri:Area/Main/Merge">001882</idno>
<idno type="wicri:Area/Main/Curation">001876</idno>
<idno type="wicri:Area/Main/Exploration">001876</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Recent developments on coronavirus main protease/3C like protease inhibitors.</title>
<author><name sortKey="Zhao, Qi" sort="Zhao, Qi" uniqKey="Zhao Q" first="Qi" last="Zhao">Qi Zhao</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520, USA. qi.zhao@yale.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weber, Erin" sort="Weber, Erin" uniqKey="Weber E" first="Erin" last="Weber">Erin Weber</name>
</author>
<author><name sortKey="Yang, Haitao" sort="Yang, Haitao" uniqKey="Yang H" first="Haitao" last="Yang">Haitao Yang</name>
</author>
</analytic>
<series><title level="j">Recent patents on anti-infective drug discovery</title>
<idno type="eISSN">2212-4071</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Crystallography, X-Ray</term>
<term>Cysteine Endopeptidases (chemistry)</term>
<term>Cysteine Endopeptidases (metabolism)</term>
<term>Drug Design</term>
<term>Drug Evaluation, Preclinical (methods)</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Patents as Topic</term>
<term>Protease Inhibitors (chemistry)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Brevets comme sujet</term>
<term>Conception de médicament</term>
<term>Cristallographie aux rayons X</term>
<term>Cysteine endopeptidases ()</term>
<term>Cysteine endopeptidases (métabolisme)</term>
<term>Humains</term>
<term>Inhibiteurs de protéases ()</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Structure moléculaire</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Évaluation préclinique de médicament ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Cysteine Endopeptidases</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cysteine Endopeptidases</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cysteine endopeptidases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Crystallography, X-Ray</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Patents as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Brevets comme sujet</term>
<term>Conception de médicament</term>
<term>Cristallographie aux rayons X</term>
<term>Cysteine endopeptidases</term>
<term>Humains</term>
<term>Inhibiteurs de protéases</term>
<term>Structure moléculaire</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronaviruses have been thrust into the spotlight by the recurring novel human coronavirus infections following the 2003 SARS pandemic. In the years since the initial SARS outbreak, the arsenal to fight this virus family has been significantly increased by the rapid growth of coronavirus research. Among the potential viral drug targets, coronavirus 3C like proteases (3Cl) have emerged as the most popular drug target. A number of patented inhibitors with promising clinical potential have been developed via different methods of drug discovery, including virtual screening, natural product isolation and structure assisted rational drug design. This review serves as a summary of the progress in both the method of drug discovery and the related inhibitors against the coronavirus 3Cl protease. </div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Connecticut</li>
</region>
</list>
<tree><noCountry><name sortKey="Weber, Erin" sort="Weber, Erin" uniqKey="Weber E" first="Erin" last="Weber">Erin Weber</name>
<name sortKey="Yang, Haitao" sort="Yang, Haitao" uniqKey="Yang H" first="Haitao" last="Yang">Haitao Yang</name>
</noCountry>
<country name="États-Unis"><region name="Connecticut"><name sortKey="Zhao, Qi" sort="Zhao, Qi" uniqKey="Zhao Q" first="Qi" last="Zhao">Qi Zhao</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001876 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001876 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:23879823 |texte= Recent developments on coronavirus main protease/3C like protease inhibitors. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23879823" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |